Focus: Glaukos is a public ophthalmology-focused medical device and specialty pharmaceutical company headquartered in Aliso Viejo, CA, with FY2025 revenue of $315M. The company specializes in glaucoma devices and corneal cross-linking treatments, competing in niche ophthalmology markets.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Glaukos to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Glaukos's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Multiple ANDA formulations of mitomycin represent 50% of revenue but face commoditization pressure post-LOE; primary cash generator but low-margin and vulnerable to generic competition.
Help build intelligence for Glaukos
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Multiple ANDA formulations of mitomycin represent 50% of revenue but face commoditization pressure post-LOE; primary cash generator but low-margin and vulnerable to generic competition.
Additional generic mitomycin ANDA formulation contributing to portfolio diversification but facing same commoditization and margin compression risks.
Brand mitomycin formulation with approaching LOE; faces transition to generic competition within the near term.
Additional post-LOE generic formulation adding to mitomycin portfolio breadth but contributing to revenue concentration and margin pressure.
Branded riboflavin formulation for corneal treatments; LOE approaching in October 2028 creates near-term revenue cliff risk.
Additional post-LOE generic mitomycin contributing to portfolio saturation and continued commoditization exposure.
At peak revenue stage; key branded asset in ophthalmology and likely a margin driver within specialty portfolio; represents successful specialty differentiation.
Brand mitomycin formulation with patent cliff in May 2029; another revenue contributor facing near-term generic erosion.
Growth-stage intracameral implant for glaucoma with LOE not until February 2031; emerging revenue driver and differentiator from generic mitomycin portfolio.
2 discontinued, 6 duplicate formulations not shown
Glaukos Corporation (GKOS) Stock Price, News & Analysis - Stock Titan
Glaukos Corporation (GKOS) Stock Price, News & Analysis Stock Titan
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - TradingView
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? TradingView
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery - BioSpace
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery BioSpace
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases - BioSpace
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases BioSpace
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus - BioSpace
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus BioSpace
Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28 - BioSpace
Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28 BioSpace
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo